Transforming technology into health
Autem Medical is a startup digital company founded in 2017 in New Hampshire, USA, by Dr. Frederico Perego Costa, a medical oncologist trained at Memorial Sloan Kettering Cancer Center in New York and specialized in the treatment of hepatocellular carcinoma (HCC) and other gastrointestinal malignancies. He is a practicing medical oncologist at Hospital Sírio Libanês, São Paulo Brazil.
Autem Medical is developing the gEM medical device, which we believe – based on promising studies – will be used to treat patients with HCC and other cancers. The medical device is composed of communication technology and a Network Software Platform that includes storage and data processing for the patient-specific treatment of HCC.
Autem Medical is developing a new treatment option for advanced cancer patients using the gEM medical device.
Based on promising studies, the Autem gEM will be used to treat patients with HCC and other cancers. The medical device is composed of communication technology and a Network Software Platform that includes storage and data processing for the identification of patient-specific frequencies (PSF) targeted to treat of cancer.
The Autem Medical technology we are developing uses safe and low levels of radiofrequency electromagnetic fields (that emit less energy than a cell phone). We believe this will allow the targeted cancer treatment of patients using a non-invasive and non-toxic procedure.
São Paulo, SP
Future Regional Office
Frederico Costa, MD
President & Founder
Medical oncologist, co-founder and on the faculty of the Centro de Oncologia of Hospital Sírio Libanês. He is a former Medical Oncology/Hematology Fellow at Memorial Sloan-Kettering Cancer Center in New York, USA.
Global clinical development and pharmaceutical services executive, former private equity and strategy consulting partner, Bachelor in Economics from Dartmouth College and Master of Business Administration from Harvard Business School, USA.
Chief of Business Development
Life Sciences Executive with expertise in Licensing, Mergers and Acquisitions, and a record of serial successful exit transactions with Medivation, InterMune, Chiesi, ImClone and CollaGenex. Juris Doctor from Stanford.
Vice-president & Commercial Operations
Marketing/Business Strategy, former Head of Oncology Unit for Merck Serono and Baxter, Director Baxter medical devices, Bachelor in Biomedicine and Master in Business Administration from Fundação Getulio Vargas, Brazil.
Master and PhD in Physics and Computer Science, Prof. and Chairman of Division of Experimental Oncology, Cross Cancer Institute, University of Alberta, Edmonton, Canada.
Chief of Product Development
Senior Regulatory Engineer, expert in R&D, manufacturing, and business development in the medical device industry. Principal consultant of Medcatalyst Consulting LLC, Highland Park, IL, USA.
Chief of Quality Management & Regulatory
Senior Regulatory Expert with wide experience in global product development and commercialization including quality, regulatory and clinical trials. Principal consultant of Paladin Biomedical Consultants LLC, Monroe, GA, USA.
Chief of Mathematics & Statistics
Master in Mathematics from University of São Paulo, Brazil and PhD in Statistics from FSAGx, Belgium and University of Marseille, France; expertise in probabilistic and applied statistics with focus in experimental design and process optimization.
Flavio Soares Correa
Scientific and Academic Advisor
PhD in Artificial Intelligence (University of Edinburgh, UK, 1992), Associate Professor at the University of Sao Paulo (Brazil), Honorary Research Fellow at the University of Aberdeen (UK), elected Senior Member of the Association of Computing Machinery (USA) and of the Society for Studies of Artificial Intelligence and Simulation of Behaviour (UK).
Experienced life science executive with global leadership roles. Currently CEO at Geistlich Pharma North America Inc; formerly President and CEO, PuriCore plc, and VP/GM, Baxter. Bachelor in Public Policy from Duke University and MBA from DePaul University.